Interstitial lung diseases (ILDs) represent a heterogeneous group of more than 200 diseases that affect the lung interstitium. These conditions, characterized by varying degrees of inflammation and fibrosis, present a diagnostic and therapeutic challenge for healthcare professionals due to their complex etiology and clinical presentation.
ILDs can be classified into idiopathic and secondary forms. The idiopathic forms, including idiopathic pulmonary fibrosis (IPF), are of unknown cause. Secondary ILDs can occur due to systemic diseases, occupational exposure, drugs, and radiation. Understanding the cause is crucial, as it greatly influences the management and prognosis of the disease.
Patients with ILDs often present with non-specific symptoms such as dyspnea and cough. The diagnosis of ILDs involves a comprehensive assessment including clinical evaluation, radiological imaging, and sometimes, lung biopsy. High-resolution computed tomography (HRCT) is the gold standard imaging technique for ILDs, providing detailed information about the lung architecture.
The management of ILDs is complex and depends on the underlying cause. For IPF, antifibrotic drugs such as pirfenidone and nintedanib have shown to slow disease progression. In secondary ILDs, treating the underlying cause is paramount. Lung transplantation may be an option for selected patients with advanced disease. The prognosis of ILDs varies widely, with IPF having the worst survival rates.
Interstitial lung diseases are a diverse group of disorders with a complex etiology and clinical presentation. Accurate diagnosis and appropriate management are key to improving patient outcomes. As healthcare professionals, staying updated on the latest advancements in the field is vital to provide optimal care to patients with these challenging conditions.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation